Objective: To explore the predictive value of the atherogenic index of plasma (AIP), triglyceride-glucose (TyG) index, and cerebral small vascular disease (CSVD) imaging load score regarding the early prognosis of patients with acute ischemic stroke (AIS) after intravenous thrombolysis. Methods: A total of 379 inpatients (diagnosed with AIS at the Shengli Oilfield Central Hospital and treated with intravenous thrombolysis from January 2022 to December 2023) were retrospectively analyzed. Relevant data were collected, and the CSVD imaging load score was evaluated. The patients were classified into the good prognosis group (≥18%) and the poor prognosis group (< 18%) based on the early neurological improvement rate 14 d after thrombolysis. An investigation into the independent risk factors influencing the early prognostic outcomes in patients suffering from AIS was conducted utilizing binary Logistic regression analysis. The efficacy of early prognosis prediction in patients undergoing intravenous thrombolysis was assessed through receiver operating characteristic (ROC) curve analysis. Results: Systolic blood pressure, AIP ,TyG index , neutrophil to lymphocyte ratio (NLR), cerebral microbleeds (CMB), enlarged perivascular spaces (EPVS) and a CSVD imaging load score of 2 points or higher served as independentrisk factors influencing the early prognosis in AIS patients undergoing thrombolysis. The ROC curve analysis revealed that the area under the curve (AUC) for the CSVD imaging load score was 0.821, with a sensitivity of 80.4% and a specificity of 74%. The AUC of the AIP was 0.951, with a sensitivity of 89.2% and a specificity of 91.7%. The AUC of the TyG index was 0.918, with a sensitivity of 93.1% and a specificity of 82.7%. Conclusion: The AIP, TyG index, and CSVD imaging load score serve as efficacious indicators in assessing the premature prognostication of AIS patients who underwent subsequently to intravenous thrombolytic therapy.

Parkinsons disease (PD) is a chronic, progressive neurodegenerative disorder characterized by both motor and non-motor symptoms. Pain, a key component of PDs non-motor symptoms, was first documented by Charcot in 1872 as a potential correlate of the disease. While pharmacological and surgical interventions have gained traction in managing PD-related pain, the therapeutic framework remains inconsistent. Understanding the pathogenesis and contributing factors of PD pain is crucial for developing novel therapies and refining disease identification and treatment protocols. This review examines the potential mechanisms and influencing factors of PD-associated pain, with the aim of identifying new therapeutic targets for PD pain.